| | |
| Clinical data | |
|---|---|
| Other names | CB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | Acute: 15 hours [1] Chronic: 23 days [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H30INO |
| Molar mass | 523.458 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Idoxifene (INN, USAN, BAN) (former developmental code names CB-7432, SB-223030), also known as pyrrolidino-4-iodotamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group which was under development for the treatment of breast cancer and postmenopausal osteoporosis but was never marketed. [1] [2] [3] It reached phase III clinical trials for postmenopausal osteoporosis and phase II clinical trials for breast cancer before development was discontinued in 1999 due to insufficient effectiveness in both cases. [1]
A large-scale chemical synthesis of idoxifene has been devised. [4]